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Background: RotaTeq® pentavalent human rotavirus vaccine (RV5) is effective against rotavirus illness and
rotavirus-related hospitalizations and death. Effectiveness depends on adherence to the dosing schedule, which
includes 3 doses at ages 2, 4 and 6 months. Two studies have used automated claims databases to estimate
the proportion of vaccinated infants who complete the dosing schedule, but excluded from analysis vaccinated
infants who were not enrolled in the database for a sufficient period to observe all 3 doses. Restricting study
populations based on duration of follow-up can introduce bias if a large number of subjects are excluded due
to insufficient follow-up, and if their outcomes differ from subjects who are included. To address the possibility
that exclusions may have been extensive and led to biased estimates of completion rates, we conducted a
claims database analysis in the HealthCore Integrated Research DatabaseSM to evaluate the proportion of
rotavirus vaccinated infants who completed the 3 dose series of RV5. We evaluated potential error introduced
by restricting analyses to infants with complete follow-up by estimating completion rates among infants with
complete follow-up, and using Kaplan-Meier analyses to estimate completion rates including infants with
incomplete follow-up.
Results: The inclusion criterion requiring continuous enrollment for the first year of life resulted in only 108,533
(40%) of 233,143 vaccinated infants from 2006–2012 being included in the analysis. After relaxing inclusion
criteria, we were able to include 86% of vaccinated infants. The estimated completion rate among infants with
continuous enrollment from birth through the first year of life was 78.1% (95% confidence limits [CLs] 77.8%,
78.3%), and among the expanded population the estimated completion rate was 77.4% (95% CLs 77.2%, 77.6%).
Conclusions: These results indicate that most infants were not followed in the database through the first year of life,
but the impact of excluding infants with incomplete follow-up was negligible when assessing RV5 completion rates for
this commercially insured population. Nonetheless, to increase the size of study populations and reduce the potential
for bias, it is preferable to include subjects with incomplete follow-up in automated database analyses, and adopt more
robust approaches to defining and analyzing study populations that account for missing data.
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Rotavirus is a common cause of severe gastroenteritis
among infants. There are two live rotavirus oral vaccines
marketed in the US, RV5 (RotaTeq® pentavalent human
rotavirus vaccine, Merck & Co., Inc.) approved in 2006,
and RV1 (Rotarix® monovalent human rotavirus vaccine,
GlaxoSmithKline Biologicals) approved in 2008 [1]. Each
vaccine is supported by the Advisory Committee on
Immunization Practices (ACIP) and the vaccines are ef-
fective against rotavirus illness and rotavirus-related hos-
pitalizations and death [1]. In a recent study, 89% of
infants receiving rotavirus vaccination received RV5 [2].
The effectiveness of RV5 depends on adherence to the
dosing schedule, which includes 3 doses at ages 2, 4 and
6 months of age [1]. The recommended maximum age
for the first RV5 dose is 14 weeks, and the third RV5
dose should be administered by 8 months of age [1].
Two automated database studies used commercial in-
surance claims and estimated the proportion of rotavirus
vaccinated infants completing all 3 doses of RV5 as 79%
and 83% [2,3]. Because vaccination is associated with
specific procedure codes and payments, claims databases
should have excellent completeness in recording vacci-
nations for members who receive them during periods
of enrollment. Claims databases represent dynamic pop-
ulations, however, in which infants enter and exit the
database when they obtain or terminate health insurance
coverage (e.g., because their parents acquire or lose in-
surance coverage or change insurance carriers). There-
fore, if an infant enters a database after receiving an
initial vaccination, there will be no record of the first
vaccination in the database. Similarly, after insurance
coverage is terminated, the database will contain no evi-
dence of any subsequent vaccinations. To address miss-
ing data due to incomplete follow-up, previous database
studies restricted analyses to infants with sufficient dur-
ation of database enrollment to observe all 3 rotavirus
vaccine doses if they were administered. Krishnarajah
et al. [2] included infants continuously enrolled from
1 month of age through 9 months of age, and Panozzo
et al. [3] included infants who were continuously en-
rolled from birth through 11 months of age.
Restricting study populations based on duration of
follow-up can introduce bias if a large number of sub-
jects are excluded due to insufficient follow-up, and if
their outcomes differ from subjects who are included
[4,5]. Neither Krishnarajah et al. [2] nor Panozzo et al.
[3] provided sufficient data to estimate the percentage of
infants excluded due to incomplete follow-up. To the
extent that these US commercial insurance claims data-
bases have similar durations of enrollment, our results
(below) indicate that this percentage could have been
very large in both studies. To address concerns that ex-
tensive exclusions may have led to biased estimates ofcompletion rates, we conducted a claims database ana-
lysis to evaluate the proportion of rotavirus vaccinated
infants who complete the 3 dose series of RV5 (comple-
tion rates), and to evaluate potential error introduced by
restricting analyses to infants with complete follow-up.
Specifically, we examined (a) the proportion of infants
that might be excluded due to insufficient follow-up,
and (b) the potential impact on RV5 completion rates of
infants who are excluded.
Methods
We conducted a retrospective study using the Health-
Core Integrated Research DatabaseSM (HIRD). The
HIRD is an automated database comprising medical and
pharmacy insurance claims data from approximately 38
million health plan members across the United States.
Member enrollment, medical care (professional and fa-
cility claims), outpatient prescription drug use, out-
patient laboratory test result data, and health care
utilization are tracked longitudinally for health plan
members in the database since January 2006.
We identified all infants who received at least 1 dose
of RV5 during the first year of life between February 1,
2006 and November 30, 2012. For the initial cohort ex-
traction, we did not require any continuous period of
enrollment or that first enrollment occur by any specific
age; instead, we included any infant who had at least 1
dose of RV5 between birth date and first birthday to
identify as completely as possible all vaccinated infants.
Exposure to RV5 was identified using medical claims
with Current Procedural Terminology (CPT) code
90680. For all infants identified, information was col-
lected on dates of all RV5 vaccinations, geographic re-
gion of residence, and insurance coverage information.
To evaluate completion, we first identified infants with
complete follow-up (complete case analysis). Among the
cohort of infants having received at least 1 dose of RV5
in the first year of life, we identified infants who were
continuously enrolled in the health plan from birth
through their first birthday.
To include infants with incomplete follow-up, we
sought to identify infants for whom the first dose of RV5
recorded in the database was in fact the first dose of
RV5. We examined RV5 doses administered by infant
age to examine age ranges during which different doses
occurred. To exclude as few infants as possible, we de-
termined the latest age for which we could be confident
that no vaccination would have been given earlier, so
that the next vaccination received would be the first
dose. We then followed these infants for RV5 vaccin-
ation as long as they remained in the database.
Among infants with complete follow-up through the
first year of life, we computed completion rates as the
proportion of vaccinated infants receiving all 3 doses
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enrollment during the first year of life, and for whom we
could determine the first dose, we computed completion
rates using Kaplan-Meier analyses with right censoring
upon the earliest of receipt of the third dose, termin-
ation of database enrollment, or end of the follow-up
period (Cohort B). To evaluate change over time in
completion rates, we stratified results according to cal-
endar periods 2006–08 and 2009–12. The calendar
period stratum was assigned according to the date the of
the first RV5 dose. Confidence limits (CLs) were com-
puted using the Wald method for binomial data [6].
Results
We identified 272,142 infants in the database having at
least 1 dose of RV5 in the first year of life. Among these
infants, we identified 108,533 (39.9%) infants who were
enrolled continuously from birth through the first year
of life (Figure 1, Cohort A). Cohort A was followed for
108,553 person-years. To increase the size of the study
population, we examined the distribution of first doses
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Figure 1 RotaTeq® (RV5) cohort formation in the HealthCore
Integrated Research DatabaseSM (HIRD).infants receive any doses of RV5 (Figure 2). In the over-
all cohort, we observed that the first dose occurred prior
to 4 weeks of age for 0.02% and prior to 6 weeks of age
for 0.2%. Based on the small probability of having dose 1
before 6 weeks of age, we relaxed the requirement that
infants be enrolled at birth to include infants enrolled by
6 weeks of age. We also dropped the requirement for a
minimum duration of follow-up. This expanded group
included 233,143 (85.7%) infants enrolled by 6 weeks of
age (Figure 1, Cohort B). Cohort B was followed for
193,438 person-years. By including infants with incom-
plete follow-up, the proportion of vaccinated infants in-
cluded in the analysis increased from 39.9% to 85.7%,
and the proportion of infants with missing information
for dose 3 was reduced from 60.1% to 32.8% (Table 1).
The estimated completion rate among Cohort A in-
fants with continuous enrollment from birth through
the first year of life was 78.1% (95% CLs 77.8%, 78.3%;
Table 1). Among Cohort B infants enrolled from 6 weeks
of age, the estimated completion rate was 77.4% (95%
CLs 77.2%, 77.6%; Table 1).
To assess the maximum potential impact of missing
data due to incomplete follow-up, we estimated comple-
tion rates assuming that none and all of the infants with
missing information on vaccinations due to incomplete
follow-up received all 3 doses. For infants with continu-
ous enrollment for the first year of life (Cohort A), the
possible range of completion rates compatible with the
data was 31.1% to 91.2% (Table 1). By including infants
enrolled by 6 weeks of age and not requiring continuous
enrollment for the first year of life (Cohort B), the pos-
sible range of completion rates decreased to 54.5% to
85.3% (Table 1).
Comparing the time periods from 2006–2008 to
2009–2012, for infants with complete follow-up we ob-
served a decrease in completion rate from 79.5% (95%
CLs 79.1%, 79.8%; Table 1) to 76.9% (95% CLs 76.5%,
77.2%; Table 1). For the unrestricted population allowing
infants with incomplete follow-up, the completion rate
declined from 79.0% (95% CLs 78.8%, 79.3%; Table 1) to
76.2% (95% CLs 76.0%, 76.4%; Table 1).
Discussion
Automated claims databases offer researchers access to
healthcare encounters for large populations followed
over time. Two previous studies used automated claims
databases to evaluate adherence to pentavalent rotavirus
vaccination (RV5) by estimating the proportion of in-
fants receiving at least 1 dose who went on to receive
the complete schedule of 3 doses, and estimated comple-
tion rates of 79% and 83% [2,3]. These studies used a
method known in clinical trials as a “complete case ana-
lysis” [7,8] which excludes from the analysis subjects
with missing data due to incomplete follow-up who
Figure 2 Distribution of RotaTeq® doses by age in the HealthCore Integrated Research DatabaseSM (HIRD), 2006–2012. The distribution of
RotaTeq® doses by age in the HIRD among infants who received at least one dose of RotaTeq® in the first year of life, 2006–2012.
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sequences of such exclusions include (a) a smaller study
size and (b) potentially biased results if the outcomes
(e.g., completion rates) of excluded subjects differ from
subjects who are included [7,8]. In clinical trials, restrict-
ing analyses to subjects with complete data is widely dis-
couraged owing to the potential for bias [5,7-9]. Instead,
it is recommended that missing data should be quanti-
fied and that, at a minimum, sensitivity analyses should
be performed to determine the potential impact of miss-
ing data on the results [7,9].
While restricting analyses to subjects with complete data
is discouraged in clinical trials, complete case analysis is a




n = 108, 533 n
Excluded due to insufficient enrollment (%) 60.1 14
Number completing vaccine series (three doses) 84,706 14
Vaccinated infants missing information for dose 3 (%) 60.1 30
Vaccine completion rates (%) 78.1 77
(95% CI) (77.8-78.3) (7
Possible completion rates if infants with missing
doses were all unvaccinated and all vaccinated (%)
31.1-91.2 54
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2Cohort B: Enrolled by six weeks of age and no minimum follow-up.the number of subjects excluded due to missing data often
goes unreported, precluding any possibility of assessing
the potential bias. The potential for bias would be a con-
cern if a large number of subjects were excluded from
analysis. If the proportion of subjects excluded is large,
and their outcome rates differ from the outcome rates
among those included, then study results would be biased.
For instance, if a large proportion of infants were excluded
and they were less likely to complete their vaccine schedule,
the observed completion rates would be biased upward.
In light of these concerns, we used a claims database
to address the potential impact of missing data due to
incomplete follow-up on estimated completion rates of
RV5 vaccination. After identifying the total number ofnrollment requirements and calendar year of first
2006-2008 2009-2012
ohort B2 Cohort A Cohort B Cohort A Cohort B
= 233,143 n = 49,360 n = 95,018 n = 59,173 n = 138,125
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7.2-77.6) (79.1-79.8) (78.8-79.3) (76.5-77.2) (76.0-76.4)
.5 - 85.3 35.4 - 90.8 58.4 - 85.3 28.2 - 91.5 51.8 - 85.2
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only 40% of infants receiving at least 1 dose of RV5 dur-
ing the first year of life were continuously enrolled from
birth through their first birthday. After including infants
who received the first dose but who were not continu-
ously enrolled during the first year of life, we were able
to increase the proportion of vaccinated infants included
in the analyses from 40% to 86%. Although the size of
the population analyzed increased dramatically, the ob-
served RV5 completion rates declined only slightly, from
78.1% to 77.4%. Completion rates varied little over time,
suggesting temporal trends are not a major source of
variation in completion rates during the study period.
These results indicate that the impact of excluding in-
fants with incomplete follow-up in the database was
negligible when assessing RV5 completion rates in the
insured population. Duration of follow-up in the claims
database, therefore, appears to not be strongly related to
the likelihood of receiving RV5 vaccination. If study popu-
lations across different claims databases used in previous
studies were similar, excluding infants with incomplete
follow-up in previous studies of RV5 would have had little
effect on observed RV5 completion rates. By including in
the analysis infants with incomplete follow-up, the range
of possible completion rates was reduced by about 50%;
nonetheless, the data are compatible with completion
rates from 54.5-85.3%, indicating considerable uncertainty
about completion rates among these infants after they dis-
enroll from the database. This source of uncertainty due
to missing data is not reflected in the conventional confi-
dence limits, which capture only uncertainty due to ran-
dom variation, and is an order of magnitude larger than
random variation. Additional data on vaccination rates
among uninsured infants are thus needed to understand
the relation between insurance status and vaccination
rates.
Conclusion
In conclusion, restricting database analyses to infants with
complete follow-up appears to give valid estimates of RV5
completion rates for this commercially insured population.
Caution is warranted in generalizing beyond the insured
population. Nonetheless, it is preferable to include in ana-
lyses subjects with incomplete follow-up [8]. In general,
the assumption that a highly restricted population with
complete follow-up will be representative of the entire in-
sured population may not hold, hence we recommend
adoption of more robust approaches to defining and ana-
lyzing study populations that account for missing data.
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